Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Joan Bladé, Albert Oriol et al.|Blood|2019Cited by 218
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityJoaquín Martínez‐López, Jesús F. San Miguel, María‐Victoria Mateos et al.|Blood Cancer Journal|2020Cited by 78
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, Britte Kranenburg et al.|Clinical Cancer Research|2019Cited by 71
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencingYanira Ruiz‐Heredia, Joaquín Martínez‐López, Beatriz Sánchez-Vega et al.|Haematologica|2018Cited by 15
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple MyelomaTimothy Brighton, Hartmut Goldschmidt, Simon J. Harrison et al.|Blood|2017Cited by 6